---
title: "Aziyo Biologics Earnings Call: Cash, Risk and 41X"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278958379.md"
description: "Aziyo Biologics Earnings Call: Cash, Risk and 41X"
datetime: "2026-03-13T00:04:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278958379.md)
  - [en](https://longbridge.com/en/news/278958379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278958379.md)
---

# Aziyo Biologics Earnings Call: Cash, Risk and 41X

Aziyo Biologics Earnings Call: Cash, Risk and 41X

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [CDMO.US](https://longbridge.com/en/quote/CDMO.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)

## Related News & Research

- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [Revolution Medicines' experimental cancer pill helps improve survival in late-stage study](https://longbridge.com/en/news/282540793.md)
- [Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform](https://longbridge.com/en/news/282587297.md)